Wearable Devices raises $3.3M in private placement for AI6 Labs expansion
Wearable Devices Ltd. secured $3.3 million in gross proceeds from a single institutional investor through a private placement priced at $3.285 per share and warrant. The funds are designated for AI6 Labs expansion, Mudra device commercialization, and general corporate needs, with closing expected on August 3, 2026.

*this image is generated using AI for illustrative purposes only.
Wearable Devices Ltd. (NASDAQ: WLDS) announced on July 31, 2026, that it has entered into a securities purchase agreement to raise approximately $3.3 million in gross proceeds through a private placement of ordinary shares and warrants. The transaction involves the sale of 1,000,000 ordinary shares and warrants to purchase up to 1,000,000 additional shares to a single institutional investor at a combined price of $3.285 per share and warrant. This capital infusion is designed to accelerate the company’s strategic focus on AI-powered touchless sensing technologies, specifically funding its AI6 Labs initiatives and the commercialization of its Mudra product line.
The offering was priced at-the-market under Nasdaq rules and above the last closing price. The warrants issued carry an exercise price of $3.16 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance. A.G.P./Alliance Global Partners is acting as the sole placement agent for the transaction. The closing of the offering is expected to occur on or about August 3, 2026, subject to customary closing conditions.
| Offering Component | Details |
|---|---|
| Gross Proceeds | $3.3 million |
| Shares Sold | 1,000,000 ordinary shares |
| Warrants Issued | Up to 1,000,000 ordinary shares |
| Price Per Unit | $3.285 (share + warrant) |
| Warrant Exercise Price | $3.16 per share |
| Warrant Expiry | Five years from issuance |
| Closing Date | On or about August 3, 2026 |
The company stated that net proceeds will be deployed for several key growth initiatives. Primary uses include the continued commercialization of Mudra products, such as the Mudra Band and Mudra Link devices designed for touch-free control of digital systems. Funds will also support the development and manufacturing of next-generation product lines and the advancement of AI6 Labs initiatives within the Physical AI and Robotics vertical. Additionally, the capital may be used for potential strategic transactions, working capital, and other general corporate purposes.
Regulatory Framework
The offer and sale of these securities are being made in reliance on an exemption from registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended, and/or Regulation D promulgated thereunder, along with applicable state securities laws. Consequently, the securities have not been and will not initially be registered under the Securities Act or applicable state securities laws. Pursuant to the securities purchase agreement, Wearable Devices has agreed to file a registration statement with the U.S. Securities and Exchange Commission covering the resale of the ordinary shares and the ordinary shares underlying the common warrants sold in this offering.
Strategic Implications
The influx of capital underscores Wearable Devices’ commitment to scaling its dual-channel business model, which combines direct-to-consumer sales with enterprise licensing. By funding the AI6 Labs ecosystem, the company aims to integrate research, products, and AI breakthroughs to enhance its position in the XR ecosystem. This move allows the firm to address both consumer needs for stylish, functional wearables in gaming and productivity, and enterprise demands for advanced input solutions in immersive environments. The ability to close this transaction quickly with a single institutional investor suggests strong market confidence in the company’s technology roadmap and its proprietary neural input touchless technology.
How might the dilution from issuing 1,000,000 new shares and warrants impact Wearable Devices' earnings per share and shareholder value in the near term?
What specific milestones or revenue targets must the Mudra product line achieve to justify the capital allocation toward its commercialization?
Could the immediate exercisability of the warrants create downward pressure on WLDS stock price if the market price exceeds the $3.16 exercise price shortly after closing?




























